sequenced samples at the McGill University and Genome Quebec Innovation Centre were discarded in order to remove common polymorphism and sequencing artefacts. Variants in candidate genes in the proband and family members were confirmed by Sanger sequencing.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from near-confluent cells using TRIzol® LS Reagent and transferred to a Purelink Mini Spin Column and processed according to manufacturer instructions (Life Technologies). RNA integrity was verified on a Bioanalyzer (Agilent) using a Nano RN A chip (Agilent). Total RNA was treated with DNase and reverse transcribed using the Maxima First Strand cDNA synthesis kit with ds DNase (Thermo Scientific). Probe based gene expression assays were designed with the Universal Probe Library (Roche) to detect TRPV4 (UPL probe 41, ccgattcctgctcgtctact / cgggttcaggagggagac), GAPDH (UPL probe 60, agccacatcgctcagacac / gcccaatacgaccaaatcc) and PPIA (UPL probe 48, cctaaagcatacgggtcctg / cctaaagcatacgggtcctg).
QPCR reactions were performed using Taqman Advanced Fast Universal PCR Master Mix (Thermo Fisher) on a Viia7 instrument (Life Technologies). Relative expression (RQ = 2 -CT ) was calculated using the Expression Suite software (Thermo Fisher), and normalization using both GAPDH and PPIA.
Sanger sequencing of cDNA
RNA from proband and control fibroblasts was isolated in TRI Reagent (Sigma) and then treated with DNaseI prior to reverse transcription with Superscript III Reverse Transcriptase (Sigma).
cDNA was PCR amplified at the region of interest using Iproof High-Fidelity DNA Polymerase (Bio-Rad) and subject to agarose gel extraction purification (Qiagen) prior to Sanger sequencing (McGill University and Genome Quebec Innovation Center, Montreal, Canada).
Expression of TRPV4-WT and TRPV4-V829WfsX3 in HEK293 cells
cDNA sequences encoding wild type and mutant TRPV4, incorporating a C-terminal FLAG, were ordered as 3 gBlocks gene fragments (IDT DNA), assembled using Gibson Assembly Master Mix (NEB) and PCR amplified using IProof High-Fidelity DNA polymerase (Bio-Rad). Assembled cDNA was cloned into pDONR221 Gateway entry vector using Gateway BP Clonase II enzyme mix and then cloned into pBabe Gateway destination vector using Gateway LR clonase II enzyme mix (Life Technologies). After PCR and each Gateway clonase reaction, cDNA sequence fidelity was verified by Sanger Sequencing. Retroviral constructs were transiently transfected into a Phoenix packaging cell line using the HBS/Ca 3 (PO 4 ) method [10] . HEK293 cells were infected 48 h later by exposure to viral media in the presence of 4 mg/ml polybrene for 24 h followed by growth in selective media (1 ug/ml puromycin) for 2-4 weeks.
Immunodetection and deglycosylation of TRPV4
Cells were grown to confluence on cell culture dishes and harvested in modified RIPA buffer.
Supernatant from the pelleted solution was diluted to 1x in 2x sample loading buffer (Bio-Rad)
supplemented with β-mercaptoethanol (Sigma) and resolved by SDS-PAGE on a 4-15% TGX precast gel (Bio-Rad). Semi-dry transfer (Bio-Rad) was used to transfer proteins to a 0.45 µm Immobilon PVDF membrane (Millipore). Membranes were incubated in blocking solution (2% BSA in TBST) for 2 hours at room temperature followed by overnight at 4°C in monoclonal mouse anti-FLAG antibody (Sigma, F3165), diluted 1:10 000 in blocking solution, or monoclonal mouse anti-α-Tubulin antibody (Sigma, T6199), diluted 1:10 000 in blocking solution. Nikon microscope with a 60× water-dipping objective (numerical aperture 1.0) and an electronmultiplying CCD camera, as described previously [11 12] . The cells were loaded with Fluo-4AM (10 µM) for 30 minutes at 30°C in the presence of pluronic acid (2.5 mg/ml) and then perfused with HEPES physiological salt solution. Bound Ca 2+ -associated changes in emission were detected by exciting at 488 nm with a solid-state laser and collecting emitted fluorescence using a 527.5/49-nm band-pass filter, with a center wavelength of 527.5 nm and a guaranteed minimum bandwidth of 49 nm. All measurements were performed at room temperature. TRPV4 Ca 2+ sparklets were analyzed within a ROI defined by a 1.7-µm 2 box (5 × 5 pixels) positioned at a point corresponding to peak TRPV4 Ca 2+ sparklet amplitude. CPA (30 µM, 10 min) was included to eliminate IP 3 Rmediated Ca 2+ signaling. The sparklet activity was recorded in the presence of CPA (baseline), or after addition of the TRPV4 agonist (GSK101) or antagonist (HC067047). Images were analyzed using custom-designed software (A. Bonev University of Vermont, USA). Displayed F/F 0 traces were filtered using a Gaussian filter with a cutoff corner frequency of 2.56 Hz. The TRPV4 channel activity at a sparklet site was determined as NP O (N, number of channels; P O , observed open probability) as described previously [12] . The sparklet activity per field was determined by adding the NP O per site for all the sites in a field over the recoding duration and expressed as NP O per field.
Construction of all-points histograms
All-points histograms were constructed as described previously [11] . ; where a, μ and σ 2 are the area, mean value and variance of the Gaussian distribution, respectively.
Calculation of burst open times
All the F/F 0 traces were filtered using a Gaussian filter and a cutoff corner frequency of 2. The heights of all four affected family members are similar to unaffected family members;
deceased father (II-1) was 168 cm; deceased mother (II-2) was 150 cm; III-1 (affected) is 158 cm; III-2 (unaffected) is 155cm; III-3 (affected) is 168 cm; III-4 (unaffected) is 172cm; III-5 (affected) is 151 cm, and III-6 (affected) is 150 cm. There is no evidence of dwarfism or short stature as found in skeletal dysplasias.
Radiographic Skeletal Surveys:
Total body radiographic skeletal surveys were undertaken on affected family members III-5 and III-6, shown for III-5 in Figures A-F , below. The surveys exclude radiographic skeletal abnormalities in the axial or appendicular skeleton suggestive of skeletal dysplasia as described [13] [14] [15] and clearly differentiate the finding of osteonecrosis of the femoral head clinically and radiographically from TRPV4-associated skeletal dysplasias ( In brachyolmia, the mildest of the TRPV4-associated skeletal dysplasias, there is clinical shortening of the spine and radiographic evidence of spinal pathology (platyspondyly, narrowing of intervertebral spaces). There may be mild brachydactyly from birth and delayed carpal ossification. None of these findings were seen in affected family members. SMDK and metatropic dysplasia are more severe than brachyolmia. They are severe generalized skeletal dysplasias affecting all parts of the skeleton and resulting in severe disproportionate short stature.
In SMDK the hands may show delayed carpal ossification but this is not always apparent. None of these features were seen in affected family members.
Partial radiographic skeletal surveys were undertaken on affected family members III-1 and III-3, and unaffected family member III-4, also excluding radiographic axial or appendicular skeletal dysplasias and showing no radiographic evidence of scoliosis. Table E) . (Figure 1, manuscript) . She started to have pain at approximately 30 years of age and was diagnosed with bilateral hip osteonecrosis at age 38. She has subsequently progressed to stage V-VI bilaterally and recently underwent bilateral total hip arthroplasty.
III-6 On X-ray radiograph, Stage IV disease of left hip and Stage III on right. On MRI, she has Stage IV disease of both hips (Figure 1, manuscript) . Hip pain started at the age of 20 with limping. She was diagnosed at the age of 21 with bilateral osteonecrosis of the hips. She has undergone right hip core decompression and bone grafting (a common procedure for osteonecrosis) at the age of 28. S1 ). Wildtype for the TRPV4 mutation.
